Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.08
MYL's Cash-to-Debt is ranked lower than
94% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. MYL: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
MYL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.77 Max: N/A
Current: 0.08
Equity-to-Asset 0.32
MYL's Equity-to-Asset is ranked lower than
85% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. MYL: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
MYL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.44 Max: 0.9
Current: 0.32
0.19
0.9
Interest Coverage 2.15
MYL's Interest Coverage is ranked lower than
91% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. MYL: 2.15 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.61 Max: 9.19
Current: 2.15
0.83
9.19
Piotroski F-Score: 3
Altman Z-Score: 1.00
Beneish M-Score: -2.65
WACC vs ROIC
11.20%
4.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 7.86
MYL's Operating Margin % is ranked lower than
52% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. MYL: 7.86 )
Ranked among companies with meaningful Operating Margin % only.
MYL' s Operating Margin % Range Over the Past 10 Years
Min: 5.8  Med: 16.36 Max: 26.53
Current: 7.86
5.8
26.53
Net Margin % 2.50
MYL's Net Margin % is ranked lower than
65% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. MYL: 2.50 )
Ranked among companies with meaningful Net Margin % only.
MYL' s Net Margin % Range Over the Past 10 Years
Min: -3.53  Med: 9.01 Max: 14.68
Current: 2.5
-3.53
14.68
ROE % 2.47
MYL's ROE % is ranked lower than
67% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.12 vs. MYL: 2.47 )
Ranked among companies with meaningful ROE % only.
MYL' s ROE % Range Over the Past 10 Years
Min: -14.72  Med: 14.57 Max: 29.99
Current: 2.47
-14.72
29.99
ROA % 0.98
MYL's ROA % is ranked lower than
66% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. MYL: 0.98 )
Ranked among companies with meaningful ROA % only.
MYL' s ROA % Range Over the Past 10 Years
Min: -2.47  Med: 4.61 Max: 9.21
Current: 0.98
-2.47
9.21
ROC (Joel Greenblatt) % 11.06
MYL's ROC (Joel Greenblatt) % is ranked lower than
57% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. MYL: 11.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.06  Med: 31.19 Max: 47.2
Current: 11.06
11.06
47.2
3-Year Revenue Growth Rate 5.40
MYL's 3-Year Revenue Growth Rate is ranked lower than
51% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. MYL: 5.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 5.4
-6.1
54.5
3-Year EBITDA Growth Rate 5.20
MYL's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. MYL: 5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.4  Med: 11.2 Max: 107.9
Current: 5.2
-20.4
107.9
3-Year EPS without NRI Growth Rate 3.80
MYL's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. MYL: 3.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.1  Med: 3.8 Max: 110.4
Current: 3.8
-29.1
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MYL Guru Trades in Q1 2016

Joel Greenblatt 837,728 sh (+9178.19%)
Vanguard Health Care Fund 26,679,385 sh (+10.00%)
John Paulson 23,335,861 sh (+2.38%)
David Einhorn 2,890,000 sh (unchged)
John Paulson 611,200 sh (unchged)
Keeley Asset Management Corp Sold Out
Louis Moore Bacon Sold Out
David Tepper Sold Out
Steven Cohen Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Tom Russo 5,395 sh (-7.78%)
Scott Black 42,509 sh (-13.21%)
Paul Tudor Jones 6,455 sh (-20.31%)
Mario Gabelli 17,000 sh (-35.73%)
Pioneer Investments 54,144 sh (-88.47%)
» More
Q2 2016

MYL Guru Trades in Q2 2016

Lee Ainslie 2,294,698 sh (New)
David Einhorn 4,945,000 sh (+71.11%)
Paul Tudor Jones 9,355 sh (+44.93%)
Vanguard Health Care Fund 27,965,385 sh (+4.82%)
Pioneer Investments 54,144 sh (unchged)
Paul Tudor Jones 80,000 sh (unchged)
John Paulson 1,030,400 sh (unchged)
Tom Russo Sold Out
Joel Greenblatt Sold Out
Scott Black 41,144 sh (-3.21%)
John Paulson 22,028,061 sh (-5.60%)
Mario Gabelli 14,000 sh (-17.65%)
» More
Q3 2016

MYL Guru Trades in Q3 2016

Joel Greenblatt 21,460 sh (New)
David Einhorn 6,400,000 sh (+29.42%)
Paul Tudor Jones 10,900 sh (+16.52%)
Mario Gabelli 16,012 sh (+14.37%)
Vanguard Health Care Fund 29,148,837 sh (+4.23%)
Pioneer Investments 54,839 sh (+1.28%)
Scott Black 41,176 sh (+0.08%)
John Paulson 940,400 sh (unchged)
John Paulson 21,811,661 sh (-0.98%)
Lee Ainslie 1,336,436 sh (-41.76%)
» More
Q4 2016

MYL Guru Trades in Q4 2016

Jim Simons 1,504,000 sh (New)
First Pacific Advisors 3,085,731 sh (New)
David Tepper 3,275,000 sh (New)
Lee Ainslie 3,799,281 sh (+184.28%)
David Einhorn 8,670,307 sh (+35.47%)
Vanguard Health Care Fund 30,084,537 sh (+3.21%)
Mario Gabelli 16,512 sh (+3.12%)
John Paulson 904,200 sh (unchged)
Joel Greenblatt Sold Out
Scott Black 40,841 sh (-0.81%)
Pioneer Investments 54,144 sh (-1.27%)
John Paulson 20,602,500 sh (-5.54%)
Paul Tudor Jones 5,500 sh (-49.54%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:SGIOY, OTCPK:ESALF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHF, NYSE:TEVA, OTCPK:HLUYY, OTCPK:TKPYY, OTCPK:IPSEY, NYSE:RDY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:VRX, NYSE:TARO, NYSE:PTHN, NAS:OPK, OTCPK:STDAF, NAS:NBIX, NAS:MDCO » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Mylan NV was incorporated in Netherlands on July 7, 2014. The Company along with its subsidiaries is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. It also operates a research and development network that delivers a robust product pipeline. The Company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Specialty segment engages in the development and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and has also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Mylan Posts Loss Amid Investigation, Settlement Pharmaceutical company joins Valeant in reporting a loss
Mylan (NASDAQ:MYL) released its third-quarter earnings Wednesday, reporting a quarterly loss and revenue growth that was below expectations. Read more...
David Einhorn Speaks on Passive Investing, Mylan, His Cheapest Stock, the Fed GuruFocus covered Einhorn at Great Investors' Best Ideas conference
Greenlight Capital hedge fund manager David Einhorn (Trades, Portfolio) joined nine other famed investors on Tuesday to talk about stocks at the annual Great Investors’ Best Ideas Investment Symposium in Dallas. Read more...
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Guru sells stakes in Health Net, Mylan, trims stake in Bristol-Myers Squibb
Samuel Isaly (Trades, Portfolio), manager of Eaton Vance Worldwide Health Sciences Fund, was an active investor in health care-related stocks long before government became involved in the sector. His transactions in the first quarter, ended Feb. 29, reflected that interest. Read more...
John Keeley Comments on Mylan Labs Guru stock highlight
Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position. Read more...

Ratios

vs
industry
vs
history
PE Ratio 82.50
MYL's PE Ratio is ranked lower than
87% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.06 vs. MYL: 82.50 )
Ranked among companies with meaningful PE Ratio only.
MYL' s PE Ratio Range Over the Past 10 Years
Min: 7.32  Med: 25.52 Max: 112.56
Current: 82.5
7.32
112.56
Forward PE Ratio 7.83
MYL's Forward PE Ratio is ranked higher than
87% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.82 vs. MYL: 7.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 82.50
MYL's PE Ratio without NRI is ranked lower than
87% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.19 vs. MYL: 82.50 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.32  Med: 25.52 Max: 112.56
Current: 82.5
7.32
112.56
Price-to-Owner-Earnings 97.83
MYL's Price-to-Owner-Earnings is ranked lower than
83% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.27 vs. MYL: 97.83 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.15  Med: 35.07 Max: 122.57
Current: 97.83
13.15
122.57
PB Ratio 1.90
MYL's PB Ratio is ranked higher than
66% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. MYL: 1.90 )
Ranked among companies with meaningful PB Ratio only.
MYL' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.6 Max: 7.02
Current: 1.9
0.64
7.02
PS Ratio 2.09
MYL's PS Ratio is ranked higher than
60% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. MYL: 2.09 )
Ranked among companies with meaningful PS Ratio only.
MYL' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.81 Max: 4.71
Current: 2.09
0.4
4.71
Price-to-Free-Cash-Flow 12.90
MYL's Price-to-Free-Cash-Flow is ranked higher than
74% of the 185 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.92 vs. MYL: 12.90 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 19.68 Max: 119.2
Current: 12.9
8.82
119.2
Price-to-Operating-Cash-Flow 9.19
MYL's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.34 vs. MYL: 9.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 12 Max: 40.9
Current: 9.19
6.07
40.9
EV-to-EBIT 75.51
MYL's EV-to-EBIT is ranked lower than
93% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.61 vs. MYL: 75.51 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.3  Med: 18.1 Max: 75.8
Current: 75.51
-10.3
75.8
EV-to-EBITDA 19.74
MYL's EV-to-EBITDA is ranked lower than
59% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. MYL: 19.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.05 Max: 23.3
Current: 19.74
-17.7
23.3
PEG Ratio 11.03
MYL's PEG Ratio is ranked lower than
91% of the 266 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYL: 11.03 )
Ranked among companies with meaningful PEG Ratio only.
MYL' s PEG Ratio Range Over the Past 10 Years
Min: 0.74  Med: 2.78 Max: 13.36
Current: 11.03
0.74
13.36
Shiller PE Ratio 94.73
MYL's Shiller PE Ratio is ranked lower than
77% of the 157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.81 vs. MYL: 94.73 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.48  Med: 83.19 Max: 173.66
Current: 94.73
14.48
173.66
Current Ratio 0.83
MYL's Current Ratio is ranked lower than
91% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. MYL: 0.83 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 3.08 Max: 8.49
Current: 0.83
0.83
8.49
Quick Ratio 0.55
MYL's Quick Ratio is ranked lower than
92% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. MYL: 0.55 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 2.52 Max: 6.76
Current: 0.55
0.55
6.76
Days Inventory 135.66
MYL's Days Inventory is ranked lower than
59% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. MYL: 135.66 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 136.05 Max: 168.24
Current: 135.66
88.95
168.24
Days Sales Outstanding 109.82
MYL's Days Sales Outstanding is ranked lower than
75% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. MYL: 109.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.32  Med: 84.21 Max: 109.82
Current: 109.82
70.32
109.82
Days Payable 77.96
MYL's Days Payable is ranked higher than
55% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. MYL: 77.96 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 44.56  Med: 72.5 Max: 101.21
Current: 77.96
44.56
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. MYL: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.5  Med: -0.8 Max: 8.6
Current: -7.5
-25.5
8.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.26
MYL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. MYL: 1.26 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.44 Max: 2.69
Current: 1.26
0.62
2.69
Price-to-Intrinsic-Value-DCF (Earnings Based) 7.72
MYL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
100% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. MYL: 7.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.15
MYL's Price-to-Median-PS-Value is ranked higher than
53% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. MYL: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.79 Max: 3.48
Current: 1.15
0.36
3.48
Price-to-Peter-Lynch-Fair-Value 13.34
MYL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
98% of the 163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MYL: 13.34 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MYL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.98 Max: 13.4
Current: 13.34
0.67
13.4
Earnings Yield (Greenblatt) % 1.29
MYL's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. MYL: 1.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.29  Med: 5.2 Max: 19
Current: 1.29
1.29
19
Forward Rate of Return (Yacktman) % 10.48
MYL's Forward Rate of Return (Yacktman) % is ranked higher than
50% of the 353 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.48 vs. MYL: 10.48 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.7  Med: 13.7 Max: 24.9
Current: 10.48
7.7
24.9

More Statistics

Revenue (TTM) (Mil) $10,300
EPS (TTM) $ 0.51
Beta1.59
Short Percentage of Float4.70%
52-Week Range $33.60 - 50.40
Shares Outstanding (Mil)535.11

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 10,984 12,731 13,024 13,364
EPS ($) 4.71 5.34 5.66 5.78
EPS without NRI ($) 4.71 5.34 5.66 5.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.13%
Dividends per Share ($)
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Drug Addiction Treatment Stocks to Watch Feb 22 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
John Paulson's Bargain Stock Jan 30 2017 
Abbott Laboratories: An Undervalued Diamond in Overvalued Markets Jan 24 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Weak Outlook on Mylan Nov 18 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Mylan Posts Loss Amid Investigation, Settlement Nov 10 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 

More From Other Websites
Drugmakers pledge restraint, but prices will still soar Feb 27 2017
Drugmakers pledge restraint, but prices will still soar Feb 27 2017
Will Mylan, Glaukos, Supernus Live Up To Q4 Growth Views Next Week? Feb 24 2017
Mylan (MYL) to Post Q4 Earnings: Will the Stock Disappoint? Feb 24 2017
Goldman Says Buy Health-Care, Retail Volatility Before Trump Address Feb 22 2017
Where Are the Best Buying Opportunities in Stocks Right Now? Feb 21 2017
Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug Feb 21 2017
Mylan's Proposed Biosimailar for Cancer Under Review in U.S. Feb 17 2017
Blog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar -... Feb 17 2017
Trump's pick to lead health agency calls EpiPen issue 'disturbing' Feb 16 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar... Feb 16 2017
Health Care Sector Led the S&P 500’s Rally on February 15 Feb 16 2017
Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC Feb 15 2017
Tepper's Appaloosa triples stake in Allergan Feb 15 2017
David Tepper Increases Wagers on Drug Companies Feb 14 2017
Mylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible... Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)